Major adverse events were significantly lower in the FUSION BIOLINE group , occurring in 17.1 % , compared with 30.7 % in the standard ePTFE group ( P = .033 ) , principally a result of a lower rate of major graft reinterventions through 12 months in the FUSION BIOLINE group ( 16.2 % vs 30.7 % ) .